The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia
Open accessAbstract
Pancreatic cancer is a highly lethal malignancy with a dismal 5-year survival of less than 5%. The scarcity of early biomarkers has considerably hindered our ability to launch preventive measures for this malignancy in a timely manner. Neutrophil gelatinase-associated lipocalin (NGAL), a 24-kDa glycoprotein, was reported to be upregulated nearly 27-fold in pancreatic cancer cells compared to normal ductal cells in a microarray analysis. Given the need for biomarkers in the early diagnosis of pancreatic cancer, we investigated the expression of NGAL in tissues with the objective of examining if NGAL immunostaining could be used to identify foci of pancreatic intraepithelial neoplasia, premalignant lesions preceding invasive cancer. To examine a possible correlation between NGAL expression and the degree of differentiation, we also analysed NGAL levels in pancreatic cancer cell lines with varying grades of differentiation. Although NGAL expression was strongly upregulated in pancreatic cancer, and moderately in pancreatitis, only a weak expression could be detected in the healthy pancreas. The average composite score for adenocarcinoma (4.26+/-2.44) was significantly higher than that for the normal pancreas (1.0) or pancreatitis (1.0) (P<0.0001). Further, although both well- and moderately differentiated pancreatic cancer were positive for NGAL, poorly differentiated adenocarcinoma was uniformly negative. Importantly, NGAL expression was detected as early as the PanIN-1 stage, suggesting that it could be a marker of the earliest premalignant changes in the pancreas. Further, we examined NGAL levels in serum samples. Serum NGAL levels were above the cutoff for healthy individuals in 94% of pancreatic cancer and 62.5% each of acute and chronic pancreatitis samples. However, the difference between NGAL levels in pancreatitis and pancreatic cancer was not significant. A ROC curve analysis revealed that ELISA for NGAL is fairly accurate in distinguishing pancreatic cancer from non-cancer cases (area under curve=0.75). In conclusion, NGAL is highly expressed in early dysplastic lesions in the pancreas, suggesting a possible role as an early diagnostic marker for pancreatic cancer. Further, serum NGAL measurement could be investigated as a possible biomarker in pancreatitis and pancreatic adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · cited 1×
“…Published online 8 April 2008 & 2008 Cancer Research UK Keywords: pancreatic cancer; diagnosis; PanIN; lipocalin; NGAL Pancreatic adenocarcinoma is one of the most aggressive cancers, with an estimated 37 000 new cases and 34 000 deaths in 2007 in the United States alone (Jemal et al, 2007).”
BackgroundGoetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Dent, C. L., Ma, Q., Dastrala, S., Bennett, M., Mitsnefes, M. M., Barasch, J., & Devarajan, P. (2007) · Critical Care · doi:10.1186/cc6192 · Cited by 483
Bauer, M., Eickhoff, J. C., Gould, M. N., Mundhenke, C., Maass, N., & Friedl, A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9619-3 · Cited by 215
Cited by
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
“For example, neutrophil gelatinaseassociated lipocalin (NGAL) is a strong biomarker for early pancreatic cancer [102] and ovarian cancer detection [103].”
BackgroundChakraborty, S., Kaur, S., Guha, S., & Batra, S. K. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.008 · Cited by 503
Self-citationBagshaw, S. M., Bennett, M., Haase, M., Haase-Fielitz, A., Egi, M., Morimatsu, H., D’amico, G., Goldsmith, D., Devarajan, P., & Bellomo, R. (2010) · Intensive Care Medicine · doi:10.1007/s00134-009-1724-9 · Cited by 328
Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer
Tummers, W. S., Willmann, J. K., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., & Swijnenburg, R.-J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001075 · Cited by 50
Metadata
- Authors
- Moniaux, N., Chakraborty, S., Yalniz, M., Gonzalez, J., Shostrom, V. K., Standop, J., Lele, S. M., Ouellette, M., Pour, P. M., Sasson, A. R., Brand, R. E., Hollingsworth, M. A., Jain, M., & Batra, S. K.
- Venue
- British Journal of Cancer
- Published
- 2008-04-08
- Volume
- 98
- Issue
- 9
- Pages
- 1540-1547
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2049092824
- Cited by
- 164
- References
- 4
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. https://app.cochat.ai/papers/10.1038/sj.bjc.6604329
- The paper
- Moniaux, N., Chakraborty, S., Yalniz, M., Gonzalez, J., Shostrom, V. K., Standop, J., Lele, S. M., Ouellette, M., Pour, P. M., Sasson, A. R., Brand, R. E., Hollingsworth, M. A., Jain, M., & Batra, S. K. (2008). Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.